Aemetis Biogas Gets CARB Approval for Six Dairy RNG Pathways

What happened

Aemetis Biogas received CARB approval for six dairy RNG pathways, as announced on November 10, 2026. This approval allows the pathways to generate LCFS credits, potentially improving the economics of the company's RNG segment. However, the company's overall financial situation remains dire, with negative equity, going concern doubts, and $286.7 million of debt due within 12 months against a $95.7 million market cap. The RNG segment has been small, contributing only $4 million in revenue in Q3 2025 from 12 digesters, and the company has yet to achieve sustained profitability. While this is a positive regulatory step, it does not address the fundamental balance sheet and liquidity challenges that currently dominate the investment thesis.

Implication

Longer-term, successful RNG ramp-up with CARB-approved pathways could improve segment profitability and LCFS credit revenue, but it requires significant additional capital and operational execution. Even then, the company must resolve its debt overhang and achieve positive FCF across segments to justify a higher valuation; otherwise, the equity remains a high-risk option with possible zero outcome.

Thesis delta

The CARB approval is a positive regulatory development for the RNG segment, but it does not address the company's severe balance sheet and liquidity issues. The STRONG SELL rating remains unchanged, as the fundamental risks of high debt, negative equity, and going concern doubt far outweigh this incremental progress. A reassessment would require evidence of sustained profitability, refinancing success, or substantial cash flow growth.